Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/660439


Czech Republic Pharmaceuticals and Healthcare Report Q4 2008


Description: The Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Czech Republic's pharmaceuticals and healthcare industry.

The US$3.64bn Czech drug market should continue to grow healthily over the forecast period, although we believe the days of double-digit growth have come to an end. Nevertheless by 2012 we expect the pharmaceutical sales to reach US$5.42bn. Prescription drugs will retain an 80%-plus market share, however, the over-the-counter (OTC) market should expand strongly.

Indeed based on the size of the market, forecasted growth and the Czech Republic’s sound Country Risk scores, We believe the Czech OTC market is one of the most attractive for investors in Central and Eastern Europe (CEE). We have also introduced a medical devices chapter into the report for Q4. The sector holds good prospects for equipment manufacturers, with the market expected to expand from US$0.75bn in 2007 to US$1.23bn in 2012. Increased private sector involvement in hospitals should help the device market outperform the pharmaceutical market through to 2012. Regulatory-wise, health fees continue to cause controversy in the sector and remain a key battleground on the political front. Shadow health minister from the senior opposition party, the Czech Social Democratic Party (CSSD), recently claimed that healthcare has become 60% more expensive for patients over the past two years a point denied by the ruling coalition.

The future of the reform in the Czech Republic remains ominous. Our political risk team believes that there are roughly equal chances of the current Civic Democratic Party-led (ODS) government managing to hold on to its position into 2009 and the CSSD taking the reins after a no-confidence vote. However, if the CSSD were to take power, its outspoken views on the reforms would doubtless lead to a change in direction. Our healthcare expenditure forecasts remain based on current reforms.

However, we note that there are considerable risks to predictions, particularly concerning private expenditure. Company news has been dominated by Sanofi-Aventis’ so-far unsuccessful bid to acquire Zentiva. Sanofi initially launched its bid on June 18 2008, outbidding a rival bid from Czech financial group PPF. Despite Sanofi’s current 24.9% stake in Zentiva, the French firm has so far been unable to persuade the board to accept its bid.


Contents: Executive Summary
Czech Republic Pharmaceuticals And Healthcare Industry SWOT
Czech Republic Political SWOT
Czech Republic Economic SWOT
Czech Republic Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Central And Eastern Europe Pharmaceutical Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Market Summary
Regulatory Regime
Intellectual Property Environment
Pricing And Reimbursement Issues
Healthcare Sector
Hospital Sector
Opposition to Health Fees
Industry Forecast Scenario
Overall Market Forecast
Table: Czech Republic’s Drug Market Forecast Indicators, 2004-2012
Key Growth Factors – Industry
Table: Czech Republic’s Health Expenditure Indicators, 2004-2012
Key Growth Factors – Macroeconomic
Table: Czech Republic – Economic Activity
Prescription Market Forecast
Table: Czech Republic- Prescription Market Indicators, 2005-2012 (US$mn unless otherwise indicated)
Patented Drug Market Forecast
Table: Patented Drugs Market Indicators, 2004-2012
Generics Market Forecasts
Table: Czech Republic’s Generics Market Forecast
OTC Market Forecast
Table: OTC Drugs Market Indicators, 2004-2012 (US$mn unless otherwise stated)
Medical Device Forecast
Czech Republic Medical Device Market Forecast
Export/Import Forecasts
Table: Czech Republic’s Pharmaceutical Trade Indicators, 2005-2012 (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Indicators
Key Risks To BMI’s Forecast Scenario
Competitive Landscape
Recent Company Developments
Research And Development Sector
Wholesale
Retail Sector
Company Monitor
Multinational Companies
AstraZeneca
Bristol-Myers Squibb
Sanofi-Aventis
Local Companies
Walmark
Zentiva (incorporating Sicomed)
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned AstraZeneca Bristol-Myers Squibb Sanofi-Aventis Walmark Zentiva (incorporating Sicomed)


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/660439

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 28/11/2009 21:09:35
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Czech Republic Pharmaceuticals and Healthcare Report Q4 2008
Web Address:
http://www.researchandmarkets.com/reports/660439
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €440.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 28/11/2009 21:09:35

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)